Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Preferred Shares Issued (2023 - 2024)

Historic Preferred Shares Issued for Spyre Therapeutics (SYRE) over the last 3 years, with Q3 2024 value amounting to -$220000.0.

  • Spyre Therapeutics' Preferred Shares Issued rose 9825.89% to -$220000.0 in Q3 2024 from the same period last year, while for Sep 2024 it was $168.8 million, marking a year-over-year decrease of 1444.74%. This contributed to the annual value of $197.4 million for FY2023, which is N/A changed from last year.
  • Spyre Therapeutics' Preferred Shares Issued amounted to -$220000.0 in Q3 2024, which was up 9825.89% from -$135000.0 recorded in Q2 2024.
  • Spyre Therapeutics' Preferred Shares Issued's 5-year high stood at $210.0 million during Q2 2023, with a 5-year trough of -$12.6 million in Q3 2023.